Ebola Treatment Market to Develop Rapidly by 2024

Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash, muscular pain, etc.

Get access to full summary @: http://www.persistencemarketresearch.com/market-research/ebola-treatment-market.asp

Ebola virus causes haemorrhagic fever which may lead to internal or external bleeding. The symptoms appear anywhere from 2 to 21 days after exposure to Ebola, though the average is 8 to 10 days. Diagnostic tests are now being done by ELISA (Antigen-capture enzyme-linked immunosorbent assay), Polymerase Chain Reaction, Virus Location, IgM Elisa and Immunohistochemistry testing. Few vaccines and medical treatments for Ebola are in pipeline and due to the absence of effective treatments, the pharmaceutical companies now have big opportunities in the market globally.

As per WHO, several care rehydration methods are adopted with fluid injection orally and other treatments are also taken care of which improves the survival rate. Top drug companies such as Hemispherx Biopharma, Biochryst Pharmaceuticals, Nano Vircides, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceuticals are among the key players in the global Ebola treatment market and are conducting trials on a set of experimental drugs.

The global Ebola treatment market growth is driven by the increasing incidence rates of Ebola viral infection and Ebola outbreaks. As per WHO, U.S. & U.K. governments, availability of different treatment procedures to treat Ebola is expected to drive the Ebola viral disease market growth during the forecast period. The Ebola treatment market also includes therapies for those who already have Ebola, and vaccines to prevent the deadly virus. Various drug companies and regulators in the U.S. are taking a two-pronged approach in finding a way to treat the virus. Approval of vaccines are taking a longer time but when vaccines undergo trials, adoption and availability could be a limiting factor for global Ebola treatment market growth.

On the basis of treatment type, the global Ebola treatment market can be segmented as follows: Vaccine (Under Trials), cAd3-Zebov, rVSV-Zebov, TKMEbola, AVI-7537, HEB, BCRX, NNVC, Drugs (Under Trials), Brincidofovir, ZMapp, Favipiravir, Zoloft, Vascor. On the basis of end user, the global Ebola treatment market can be segmented as follows: Hospitals, 500+ Beds, 250-499 Beds, Less than 250 Beds, Ambulatory Surgery Centres, Specialized Clinics, Army Camps (Veteran Facilities) .

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/11692

Geographically, the global Ebola treatment market is segmented into five regions, namely North America, Latin America, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA). Control measures are established in Liberia, Sierra Leone, and Guinea. Previously affected countries are Nigeria, Senegal, Spain, U.S., Mali, U.K. and Italy. Among all regions, MEA are expected to witness a high growth rate over the forecast period owing to the large number of affected population in these regions.

North America is the major contributor to the global Ebola treatment market mainly due to its pharmaceutical companies having hubs in the U.S. & Europe. MEA is recovering from medical crisis and is anticipated to have a positive landscape for the growth of the global Ebola treatment market. A healthy CAGR is projected to be registered in the global Ebola treatment market due to a surge in the number of pharmaceuticals and healthcare initiatives being undertaken globally.

The key players in the global Ebola Treatment market are: Arbutus Biopharma, GlaxoSmithKline, Johnson & Johnson Services, Inc., Hemispherx Biopharma, Inc., BioCryst Pharmaceuticals, Inc., NanoViricides, Inc., NewLink Genetics Corporation, Chimerix, Inc., Sarepta Therapeutics, Mapp Biopharmaceutical, Inc.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/11692

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, and applications.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.